2024-516127-14-01尚未招募1/2 期
(CHOPI) Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma.
Leids Universitair Medisch Centrum (LUMC)1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2024年9月12日最近更新:
试验速览
- 阶段
- 1/2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Safety and feasibility of combining percutaneous hepatic perfusion with ipilimumab and nivolumab (phase 1b part).
研究概览
简要总结
To determine safety and tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended phase II dose (RPTD) of the combination of ipilimumab plus nivolumab and PHP in patients with unresectable, histologically confirmed metastases of uveal melanoma will be evaluated in the phase Ib part of the study. The efficacy of PHP alone versus the combination of PHP with ipilimumab/nivolumab will be determined in the randomized phase II study.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age between 18-80 years World Health Organization (WHO) Performance Status 0 or I 50% or less histologically or cytologically confirmed unresectable metastatic uveal melanoma in the parenchymaof the liver Hepatic metastases, confined to or predominantly in the liver No prior systemic treatment (including chemotherapy, vaccine therapy, monoclonal Ab treatment, IL-2) Local pre-treatment of uveal melanoma metastases is allowed (resection and/or thermal ablation), except forchemotherapy containing procedures (e.g. chemoembolization) and radio-embolization, and as long as patientshave progressed with measurable disease according to RECIST 1.1 No concurrent systemic immunosuppressive medications ≥ 10mg/day prednisone or equivalent. Topical, inhaled,nasal and ophthalmic steroids, and adrenal replacement therapy are allowed. Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥ 1.0x109/L, Platelets≥ 100 x109/L, Hemoglobin ≥ 6.5 mmol/L, Creatinine ≤ 2x ULN, AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN, Total bilirubin ≤1.5 X ULN, INR and PTT ≤ 1.5 x ULN, LDH <2xULN Women of child bearing potential (WOCBP) must agree to use a reliable form of contraceptive as described in theresearch protocol Men must agree to the use of male contraception as described in the research protocol Absence of additional severe and/or uncontrolled concurrent disease No prior, or ongoing other malignancy, except adequately treated basal cell or squamous cell skin cancer, cervicalcancer in situ or adequately treated other cancer with eradicative intent for which the patient has beencontinuously disease-free for >2 years. No aberrant vascular anatomy of the liver that precludes PHP
排除标准
- •Cerebral or meningeal metastasized uveal melanoma; Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history ofsyndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo orresolved childhood asthma/atopy; Prior immunotherapy (tumor vaccine, cytokine, or growth factor); Known history of infection with Human Immunodeficiency Virus; Active infection requiring therapy, positive serology for Hepatitis B surface antigen and/or Hepatitis C ribonucleicacid (RNA); History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes (unstable orsevere angina, recent myocardial infarction), significant arrhythmias and severe valvular disease must beevaluated for risks of undergoing general anesthesia; History or evidence of clinically significant pulmonary disease e.g. severe COPD that precludes the use of generalanesthesia; Underlying medical conditions that, in the Investigator's opinion, will make the administration of study treatmenthazardous or obscure the interpretation of toxicity determination or adverse events; Latex allergy, and known hypersensitivity/allergy to ipilimumab, nivolumab, melphalan or heparin; Prior Whipple’s Surgery; Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids; History of or current immunodeficiency disease, splenectomy or splenic irradiation; prior allogeneic stem celltransplantation; Patients who are unable to be temporarily removed from chronic anti-coagulation therapy; Patients with active bacterial infections with systemic manifestations (malaise, fever, leucocytosis) are not eligibleuntil completion of appropriate therapy; Use of other investigational drugs before study drug administration for systemic malignancy; Pregnancy or nursing
结局指标
主要结局
Safety and feasibility of combining percutaneous hepatic perfusion with ipilimumab and nivolumab (phase 1b part).
Safety and feasibility of combining percutaneous hepatic perfusion with ipilimumab and nivolumab (phase 1b part).
Efficacy as measured by progression-free survival at one year comparing PHP alone versus patients with the combination of PHP with ipilimumab and nivolumab (randomized phase 2 part).
Efficacy as measured by progression-free survival at one year comparing PHP alone versus patients with the combination of PHP with ipilimumab and nivolumab (randomized phase 2 part).
次要结局
- To evaluate best overall response rate according to RECIST 1.1 and iRECIST of patients treated with PHP alone versus patients with the combination of PHP with ipilimumab and nivolumab.
- To evaluate overall survival of patients treated with PHP alone versus patients with the combination of PHP with ipilimumab and nivolumab.
研究者
H.W. Kapiteijn
Scientific
Leids Universitair Medisch Centrum (LUMC)
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaNCT07276386H. Lee Moffitt Cancer Center and Research Institute18
招募中
1 期
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver FunctionNCT07269301Pfizer26
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsColorectal CancerNon-Small Cell Lung CancerNCT07261631Novartis Pharmaceuticals180
招募中
1 期
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsNCT07278479Molecular Partners AG138
招募中
2 期
A Phase I/IIa Study of AZD8205 given alone or in Combination with Anticancer Drugs, in Participants with Advanced or Metastatic Solid Malignancies2022-502759-70-01AstraZeneca AB97